Back to Search Results
Kari Kendra
Schedule an appointment (614) 293-4320
Insurances We Accept

Highlights

  • Rated in the top 10 percent of physicians in the nation for patient satisfaction, 2016

Medical Degree

  • M.D.
    Rush Presbyterian Hospital
    6/30/1990

Residency

  • Internal Medicine
    University of Wisconsin School of Medicine
    7/1/1991 - 6/30/1993

Specialties and conditions I treat

  • Medical Oncology
  • Melanoma
  • Skin Cancers
  • Eye Cancers
  • Uveal Cancers
  • Carcinoma, Merkel Cell
  • Melanoma, Amelanotic
  • Melanoma, Experimental
  • Hutchinson's Melanotic Freckle
  • Carcinoma, Basal Cell
  • Carcinoma, Basosquamous
  • Carcinoma, Squamous Cell
  • Basal Cell Nevus Syndrome
  • Bowen's Disease
  • Basal Cell Cancer
  • Squamous Cell Cancer
  • Neuroectodermal Tumor, Melanotic
  • Nevi and Melanomas

Locations where I practice

Please note: Not all physicians schedule patients at each listed location. Please call the “Schedule an appointment” number shown above for scheduling assistance.

More about my work

My background

Fellowships

  • Medical Oncology
    University of Rochester School of Medicine
    7/1/1998 - 6/30/2001
  • Medical Oncology
    University of Wisconsin School of Medicine
    7/1/1994 - 6/30/1996

Board Certifications

American Board of Internal Medicine
8/20/1997

American Board of Internal Medicine (Subspecialty: Medicine Oncology)
11/3/1999

My Department

Internal Medicine

My Division

Medical Oncology

Industry Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.

As of 03/25/2016, Dr. Kendra has reported no financial relationships with medical device, research and/or drug companies.